Download the Conference Program (PDF)

---

101

Lam et   al.

Descriptive   analysis of the efficacy and safety of radiosynoviorthesis in a Singaporean   tertiary hospital

102

Iakovou et   al.

Erbium-169   Radiosynoviorthesis Following Surgery for Ankle pigmented villonodular   synovitis-PVNS: Long-Term Outcomes 

from a   Rare Disease Cohort with 63-Month Median Follow-Up

103

Iakovou et   al.

Long-Term   Outcomes of Adjuvant Erbium-169 Radiosynoviorthesis for Ankle Pigmented   Villonodular Synovitis in Young Athletes: A 46-Month Follow-Up Study

104

Koutsikos   et al.

Factors   affecting 48hr 131I Residual Activity in Radioactive therapy (RAIT) in   patients with well-differentiated thyroid cancer (WDTC)

105

Tsangaridi   et al.

From   Conventional Care to Connected Care: Empowering Thyroid Cancer Patients   Through a Smart App That Actually Makes a Difference.

106

Tsangaridi   et al.

Looking   Beyond the Gland: Radiomics Redefines Response Prediction in Differentiated   Thyroid Cancer.

107

Hertz

Dr Saul Hertz RAI : The Birth of ZTHeranostics

108

Biswas et   al.

Evaluating   recurrent thyroid carcinoma: Pivotal role of high resolution ultrasonography   where 131 I-whole body scan is negative 

and not   significantly raising thyroglobulin (Tg) level

109

Yang et   al.

Radio-Iodine   labeled anti-GD2 antibody (APN311) as a theranostic radiopharmaceutical for   neuroblastoma xenograft tumors

110

Chatti et   al.

Therapeutic   Value of 18F-FDG PET/CT in Monitoring Cutaneous and Mucosal Melanoma:   Preliminary Experience from Sousse

111

Chatti et   al.

Clinical   Value and Limitations of 18F-FDG PET/CT in Neuroendocrine Tumors: A Tunisian   experience

112

Skouridi et   al.

Preliminary   Validation of Q. Thera AI Dosimetry Application for mCRPC Patients Undergoing   PSMA-Targeted Lu-177 Therapy

201

Paschali et al.

Can we predict response in   PSMA radioligand therapy? A single center retrospective study assessing PSMA   imaging phenotype parameters- 

in the theranostic setting-   with treatment response

202

dos Santos Loureiro et al.

Retrospective analysis of   metastatic castration-resistant prostate cancer patients treated with   177Lu-PSMA-617 Radioligand therapy in Uruguay

203

Jubilee et al.

Manufacture and   characterisation of radiolabelled pH-sensitive liposomes for the delivery of   docetaxel in Prostate Cancer

204

Dureja et al.

Response-Adapted PSMA   Radioligand Therapy Without Dosimetry: A Feasible Model for Low-Resource   Settings

205

Prisacariu et al.

Vascular Flip-Flop:   Theranostic Transition In Oncocytic Thyroid Carcinoma

 206

Lim et al.

The combination of   225Ac-DOTA-rituximab and lanatoside C augmented cytotoxicity in lymphoma   cells

 207

Y S et al.

A Retrospective Analysis of   Lutetium-177 PRRT in Patients with Metastatic Neuroendocrine Tumors: 

Study to guide to decrease   200mci per cycle to 100mCi per cycle of Lu-177 DOTATATE therapy

208

Dash et al.

Feasibility and Safety of   161Tb-FAP2268 Peptide Targeted Radionuclide Therapy in Solid Tumors:   Preliminary Clinical Insight from India

 209

Di   Santo et al.

Prognostic   implication of [¹⁸F]FDG PET and its Metabolic Changes in Patients with   Advanced Metastatic Neuroendocrine 

Tumors    Undergoing Rechallenge PRRT: Final   Results from a Multicenter 10-Years Survival

210

Sahmim et al.

How to secure therapy ? «   process mapping » could be the game-changer

211

Sergieva et al.

68Ga-FAPI PET Imaging in   Oncology

 212

Atiya et al.

Role of 68 Ga DOTA-TATE PET/CT   in the evaluation of gastroenteropancreatic neuroendocrinal tumors and its   impact on the clinical outcome